AMADIX

Description

AMADIX develops blood-based liquid biopsy tests and machine-learning software that analyze molecular biomarkers and clinical data to detect colorectal, lung, and pancreatic cancer at early, pre-symptomatic stages.

Related

• Xemperia SAXemperia SA develops blood-based diagnostic tests that detect cancer-associated biomarkers using multiomics and AI methods, and creates…
• GlycanosticsGlycanostics develops non-invasive liquid biopsy cancer diagnostics, building antibody-coated magnetic particle tests that detect glycan…
• QuibimQuibim develops cloud-based AI software that extracts quantitative radiomics and imaging biomarkers from MRI, CT and PET studies to support…
• OrixhaOrixha develops a proprietary Total Liquid Ventilation clinical platform, LuncoLive, that circulates a breathable liquid to ventilate lungs…
• EbenbuildEbenbuild develops lung digital twin technology that combines physics-based modeling with patient data to create virtual lung replicas for…
• Age LabsAge Labs develops biomarkers and predictive algorithms for early detection of age-related diseases, offering diagnostic tests, biological…
• CyclomicsCyclomics develops molecular diagnostics and DNA sequencing products including the CySeq consensus sequencing and liquid biopsy platform…
• Cyted HealthCyted Health combines minimally invasive cell collection with molecular analysis to build diagnostic tests (EndoSign®) for earlier…
• XENOTHERAXENOTHERA develops glyco humanized antibody technology for immunological treatments, lists pipeline products and clinical trials for…